Track record · closed signal

Novo Nordisk A/S (NVO) — closed signal from December 25, 2025

Target reached Published before the outcome was known, scored automatically when the window closed on March 25, 2026.

Predicted vs. what happened

NVO price · publication thesis → realized outcomesplit-adjusted

$50.50 – $52.75Entry zone — fair-value band

$52.56Published — price the day we called it

$59.92Target — the price the thesis aimed for

$64.16Peak — highest point inside the window, not a realized return

$36.33Window close — end-of-window price, context only

What happened

Target reached

Reached its target in 15 days.

Peak price

$64.16

peak on January 23, 2026 — not a realized return

Peak gain

+22.1%

peak, from the publication price

Window close

$36.33

end-of-window price, context only

Days to target

Window

December 25, 2025 – March 25, 2026

The thesis — published December 25, 2025

Predicted growth

+14%

over the measurement window

Target price

$59.92

the price the thesis aimed for

Entry zone

$50.50 – $52.75

the fair-value band we waited for

Price at publication

$52.56

published December 25, 2025

Confidence

62%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

Novo Nordisk jumped after regulators approved the first pill version of Wegovy, which drew strong buying and attention for weeks. That approval can keep interest high short term, but rivals and cheaper versions expected next March could cool enthusiasm. Right now many buyers pushed the price up quickly, so waiting for a calmer pullback is safer than chasing the run.

Primary drivers

Approval of an oral Wegovy pill lifts short-term investor interest
A surge of buying pushed the stock higher after the news
Rivals and lower-cost versions due next March can limit gains
Adds healthcare exposure to balance a tech-focused portfolio

How it played out

NVO: target reached in 15 days

Lyra published NVO at 52.56 with 14% expected growth and a 59.92 target. The thesis pointed to approval of an oral Wegovy pill, a surge of buying after the news, rivals and lower-cost versions due next March, and healthcare exposure for portfolio balance.

Inside the window, the stock reached 64.16 on 2026-01-23, with a 22.1% peak gain. It reached the target in 15 days. By 2026-03-25, it ended at 36.33. The thesis played out early on price, then the stock gave that move back by the end of the window.

What happened during the window

On 2026-01-05, The Guardian reported that Novo Nordisk launched the oral Wegovy pill in the U.S. The Washington Post also reported on 2026-01-05 that the pill was available at pharmacies and through mail-order services.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All NVO signals